FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 217 filers reported holding FATE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.68 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,460,000 | +11.8% | 65,144 | +23.1% | 0.00% | 0.0% |
| Q2 2022 | $1,306,000 | +270.0% | 52,903 | +793.3% | 0.00% | +200.0% |
| Q3 2021 | $353,000 | -40.0% | 5,922 | -12.7% | 0.00% | 0.0% |
| Q2 2021 | $588,000 | -64.5% | 6,782 | -64.4% | 0.00% | -75.0% |
| Q1 2021 | $1,658,000 | -0.8% | 19,033 | +3.4% | 0.00% | 0.0% |
| Q4 2020 | $1,671,000 | +103.0% | 18,403 | -10.9% | 0.00% | +100.0% |
| Q3 2020 | $823,000 | +48.8% | 20,645 | +28.0% | 0.00% | 0.0% |
| Q2 2020 | $553,000 | +2.8% | 16,123 | -33.4% | 0.00% | 0.0% |
| Q1 2020 | $538,000 | +657.7% | 24,206 | +455.2% | 0.00% | – |
| Q4 2018 | $71,000 | 0.0% | 4,360 | 0.0% | 0.00% | – |
| Q3 2018 | $71,000 | +44.9% | 4,360 | 0.0% | 0.00% | – |
| Q2 2018 | $49,000 | – | 4,360 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |